Effects of &lt;i&gt;L&lt;/i&gt;-Carnitine Supplementation on Renal Anemia in Poor Responders to Erythropoietin

Matsumoto, Yoshihiro; Amano, Izumi; Hirose, Shinichi; Tsuruta, Yoshinari; Murata, Michio

doi:10.1159/000014474

Cited by 56 publications

(33 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, Lcarnitine has been proposed as a potential adjuvant treatment to improve anaemia, thrombocytopenia, leukopenia and immunological function. [68][69][70][71][72][73] In a recent study, L-carnitine added to Peg-IFN-α plus ribavirin led to less decrease of platelet count during antiviral therapy. 74 Some studies indicate that L-carnitine modulates platelet functions and production through antioxidant mechanisms and the inhibition of the arachidonic acid cascade.…”

Section: L-carnitinementioning

confidence: 98%

Chronic hepatitis C-associated thrombocytopenia: aetiology and management

Fouad

2013

View full text Add to dashboard Cite

Thrombocytopenia is perhaps the most common haematological abnormality in patients with chronic hepatitis C virus (HCV) infection. In these patients, the presence of thrombocytopenia may be a limiting factor when considering antiviral therapy and may be associated with decreased sustained virological response rates. Thrombocytopenia may interfere with diagnostic procedures such as liver biopsy, because of risk of bleeding.Pathogenetic mechanisms include hypersplenism secondary to portal hypertension, bone marrow suppression resulting from either HCV itself or interferon treatment, and aberrations of the immune system resulting in the formation of anti-platelet antibodies and/or immunecomplexes that bind to platelets and facilitate their premature clearance. The ability to increase platelet levels could significantly reduce the need for platelet transfusions and facilitate the use of interferon-based antiviral therapy and other medically indicated treatments in patients with liver disease. Therapeutic options include pharmacological and non-pharmacological therapies. This review summarizes the available data on these therapeutic options. KEYWORDS: thrombocytopenia, hepatitis C virus (HCV), cytokines Definition and prevalenceThrombocytopenia has been defined as a platelet count <150,000 cells/µL. In a recent systematic review, the definitions of thrombocytopenia varied between studies and were based either on platelet counts, with threshold levels ranging between <100,000 cells/µL and <180,000 cells/µL or on criteria set in haematological guidelines. The prevalence of thrombocytopenia related to chronic liver disease has been reported as 15% to 70% in patients with advanced fibrosis and portal hypertension, depending on the stage of the disease and the platelet level used to define thrombocytopenia. In patients with chronic HCV infection, the prevalence of thrombocytopenia ranged from 0.16% to 45.4% and more than half of the studies reported a prevalence of 24% or more. 1 Aetiology of thrombocytopenia in patients with chronic HCVThe pathophysiology of thrombocytopenia in patients with HCV-related chronic liver disease is complex and involves the interaction of multiple factors. In general, these factors may be

show abstract

Section: L-carnitinementioning

confidence: 98%

Chronic hepatitis C-associated thrombocytopenia: aetiology and management

Fouad

2013

View full text Add to dashboard Cite

show abstract

“…In conclusion, the findings of this study suggest that endurance training may reverse the MICS found in ESRD that was implicated in the poor prognosis, although we could not determine whether exercise produced an anti-inflammatory effect. Previously, we have reported the effects of L-carnitine supplementation on erythropoietinresistant anemia, [34] cardiac morbidity, [35] and muscle symptoms, [36] all of which are consequences of wasting, and PEM. Most recently, Kalantar-Zadeh et al have demonstrated that an anti-inflammatory and antioxidant nutritional supplement is associated with a significant increase in the serum albumin level.…”

Section: Discussionmentioning

confidence: 99%

The Impact of Pre-Dialytic Endurance Training on Nutritional Status and Quality of Life in Stable Hemodialysis Patients (Sawada Study)

Matsumoto

Furuta²,

Furuta³

et al. 2007

Renal Failure

Self Cite

View full text Add to dashboard Cite

Background. Protein-energy malnutrition and decreased quality of life (QOL) are common in hemodialysis (HD) patients. Although several studies have proved that regular exercise has beneficial effects, few control studies have shown the effects of exercise training on the nutritional status and QOL in HD patients. Methods. Fifty-five HD patients were recruited, and 22 of them were trained to exercise on an ergometer prior to dialysis three times a week for one year. Serum albumin levels, creatinine generation rate (CGR), and the Short Form 36 were assessed as outcome measures. Results. The serum albumin levels and CGR increased in the training group compared with baseline. The QOL scores also increased in half of the physical health and mental health dimensions in the training group. Conclusion. These observations suggest that low-dose, long-term pre-dialytic endurance training might reverse the poor clinical outcome by improving the nutritional status and QOL in HD patients.

show abstract

“…Previous studies have explored whether carnitine supplementation in hemodialysis patients results in better function and longevity of the red blood cells, thus decreasing the need for ESA [9,10,11]. We previously reported that anemia, atherosclerosis, and cardiac activity were improved by oral levocarnitine therapy in hemodialysis patients [12].…”

Section: Introductionmentioning

confidence: 99%

Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia

et al. 2017

View full text Add to dashboard Cite

Aims: The aim of this study was to evaluate the efficacy of levocarnitine injection for renal anemia in hemodialysis patients. Methods: In this randomized controlled clinical trial, we randomly assigned patients on maintenance hemodialysis at our hospital to receive levocarnitine injections (n = 30) or no injection (n = 30) and monitored the patients during 12 months of treatment. In the treatment group, patients received an injection of levocarnitine 1,000 mg 3 times weekly after hemodialysis sessions. All patients received recombinant human erythropoietin as an erythropoiesis-stimulating agent (ESA). Response to ESA therapy was determined by calculating the erythropoietin responsiveness index (ERI; ESA dose·kg^-1·g^-1· dL^-1·week^-1). Results: (1) The target levels of hemoglobin and hematocrit were maintained during the study period in both the levocarnitine group and the control group. (2) The dose of ESAs required to maintain these levels decreased gradually in the levocarnitine group and was significantly lower at 6 and 12 months than at study initiation. Furthermore, the dose of ESAs was significantly lower than that in the control group at 12 months. (3) The ERI showed a significant decrease at 6 and 12 months in the levocarnitine group, with a significant difference between the 2 groups at 12 months. Conclusion: Our results suggest that levocarnitine administration can reduce the dose of ESAs required in patients with renal anemia on hemodialysis and improve the response to ESA therapy.

show abstract

Effects of <i>L</i>-Carnitine Supplementation on Renal Anemia in Poor Responders to Erythropoietin

Cited by 56 publications

References 23 publications

Chronic hepatitis C-associated thrombocytopenia: aetiology and management

Chronic hepatitis C-associated thrombocytopenia: aetiology and management

The Impact of Pre-Dialytic Endurance Training on Nutritional Status and Quality of Life in Stable Hemodialysis Patients (Sawada Study)

Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia

Contact Info

Product

Resources

About